The most significant gene was ATXN3, and its expression strongly stratified the prognosis of patients with GBM (p = 0.0089, log-rank test; 95% confidence interval [CI] ratio = 32.8–NA and 10.1–NA) (Fig. 3B). The gene discussed is ATXN3; the disease is glioblastoma.